Epigenomic subtypes and prognostic methylation signatures in clear cell renal cell carcinoma
Together, our findings demonstrate that genome-wide methylation profiling can resolve clinically relevant ccRCC subtypes, uncover novel biomarkers of disease aggressiveness, and improve patient risk stratification beyond current clinical models.
Authors
- Iben Lyskjær (ORCID: https://orcid.org/0000-0003-3446-1182)
- Niels Fristrup (ORCID: https://orcid.org/0009-0006-4442-0535)
- Line Raaby (ORCID: https://orcid.org/0000-0002-3327-9613)
- Mie Gaedt Thorlund
- Johanne Ahrenfeldt (ORCID: https://orcid.org/0000-0001-9175-0373)
- Laura Iisager (ORCID: https://orcid.org/0000-0002-5704-0586)
- Jesper Huitfeld Jespersen
- Karoline Kondrup (ORCID: https://orcid.org/0000-0003-0602-5981)
- Cecilie Lindgaard
- Anna K. Keller
- Karina D. Sørensen
- Laura Zanini
Institutions
- Aarhus University (DK)
- Odense University Hospital (DK)
- Aarhus University Hospital (DK)
Publication Details
- Journal
- Clinical Epigenetics
- Published
- 2026-01-22
- DOI
- https://doi.org/10.1186/s13148-026-02055-7
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Aarhus Universitet
- Kræftens Bekæmpelse
- Lundbeckfonden
- Harboefonden
- H. Lundbeck A/S